UroGen Pharma (TASE: URGN), which develops uro-oncological treatments, last week published positive results from two clinical trials of bladder cancer treatment UGN-102. This is
Read MoreUroGen Pharma (TASE: URGN), which develops uro-oncological treatments, last week published positive results from two clinical trials of bladder cancer treatment UGN-102. This is
Read More